Indian Pharma's Global Expansion: Major Mergers and Acquisitions on the Rise
Sun-Organon buyout shows Indian Pharma's big hunger for overseas M&As β Here's a list of other major deals
Mint
Image: Mint
Indian pharmaceutical companies are increasingly pursuing overseas mergers and acquisitions (M&As) to diversify beyond generics and adapt to market challenges. Notable recent deals include Sun Pharmaceutical's $11.75 billion acquisition of Organon and Zydus Lifesciences' potential $2.5 billion stake in Ardelyx.
- 01Indian pharma firms are focusing on international M&As to diversify their portfolios.
- 02Sun Pharmaceutical's acquisition of Organon is valued at $11.75 billion.
- 03Zydus Lifesciences is eyeing a $2.5 billion acquisition of Ardelyx.
- 04Smaller, strategic acquisitions are preferred over large deals, according to experts.
- 05Market challenges include US tariffs and a shift towards biologics.
Advertisement
In-Article Ad
Indian pharmaceutical companies are increasingly looking beyond domestic markets for growth opportunities through mergers and acquisitions (M&As). This trend is driven by challenges such as US tariff threats and price erosion in the generics market. In a significant move, Sun Pharmaceutical Industries, based in Mumbai, announced its acquisition of Organon, a US-listed women's healthcare company, for $11.75 billion. This acquisition aims to enhance long-term value and strengthen market positioning. Other notable deals include Zydus Lifesciences potentially acquiring a majority stake in Ardelyx Inc. for $2.5 billion, which would bolster its presence in the innovative medicine sector. Additionally, Intas Pharmaceuticals purchased the Udenyca franchise for $558.4 million, while Natco Pharma acquired a 35.75% stake in Adcock Ingram Holdings for $226 million. Lupin recently completed the acquisition of VISUfarma B.V. in the Netherlands for β¬190 million. These moves reflect a strategic shift among Indian drugmakers towards innovation and diversification in response to evolving market dynamics.
Advertisement
In-Article Ad
These acquisitions could lead to increased job opportunities and innovation in the Indian pharmaceutical sector, benefiting both the companies involved and the broader economy.
Advertisement
In-Article Ad
Reader Poll
Do you think Indian pharmaceutical companies should continue pursuing overseas acquisitions?
Connecting to poll...
More about Sun Pharmaceutical Industries
Read the original article
Visit the source for the complete story.




